Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Patient Symptoms Are Better Measure Of Decongestant’s Efficacy – FDA

This article was originally published in The Tan Sheet

Executive Summary

The patient self-assessed nasal congestion symptom score, not nasal air resistance, is the preferred tool to evaluate the effectiveness of an oral nasal decongestant such as phenylephrine, according to a report by a division of FDA's Office of New Drugs

Related Content

Monograph System Challenges Underscored By Pediatric Cold Debate
Phenylephrine Efficacy Will Be Questioned In Citizen Petition
Waxman Seeks Phenylephrine NDAC Review; Cites Efficacy Concerns





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts